Brief: Xbrane's Xlucane Meets Primary Endpoint In Pivotal Phase III Trial

Xbrane Biopharma AB

28/06/2021 06:33

June 28 (Reuters) - Xbrane Biopharma AB (publ)  XBRANE.ST :
    
    * SAID ON SUNDAY XLUCANE MEETS PRIMARY ENDPOINT IN PIVOTAL
PHASE
III TRIAL WITH XLUCANE
    * XLUCANE MET PRIMARY ENDPOINT DEMONSTRATING EQUIVALENT
EFFICACY
IN CHANGE OF BCVA AT WEEK 8 OF TREATMENT COMPARED TO LUCENTIS
    * CONFIRMS PLANS TO SUBMIT MAA TO EUROPEAN MEDICINES AGENCY
IN Q3
2021
    * CONFIRMS THE PLANS TO SUBMIT BLA TO US FOOD AND DRUG
ADMINISTRATION IN Q4 2021
    * WILL RECEIVE DATA ON ADDITIONAL SECONDARY ENDPOINTS AND
ANALYZE
THESE FURTHER, ALONG WITH ABOVE MENTIONED ENDPOINTS, DURING THIS
SUMMER
    * COMPLETE DATASET IS PLANNED TO BE PRESENTED IN A
SCIENTIFIC
JOURNAL OR AT A SCIENTIFIC CONFERENCE DURING 2022 AT EARLIEST

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFNRknnd
    
 Further company coverage:  XBRANE.ST  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))